Weekly Analysts’ Ratings Changes for Inspire Medical Systems (INSP)

A number of research firms have changed their ratings and price targets for Inspire Medical Systems (NYSE: INSP):

• 5/13/2026 – Inspire Medical Systems was downgraded by Zacks Research from “hold” to “strong sell”.
• 5/7/2026 – Inspire Medical Systems had its “market perform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 5/6/2026 – Inspire Medical Systems was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 5/5/2026 – Inspire Medical Systems had its price target lowered by Royal Bank Of Canada from $56.00 to $45.00. They now have a “sector perform” rating on the stock.
• 5/5/2026 – Inspire Medical Systems was given a new $55.00 price target by Evercore Inc.
• 5/5/2026 – Inspire Medical Systems was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $55.00 price target on the stock, down from $85.00.
• 5/5/2026 – Inspire Medical Systems had its price target lowered by JPMorgan Chase & Co. from $67.00 to $54.00. They now have a “neutral” rating on the stock.
• 5/5/2026 – Inspire Medical Systems had its price target lowered by Stifel Nicolaus from $70.00 to $65.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Inspire Medical Systems had its price target lowered by Truist Financial Corporation from $64.00 to $50.00. They now have a “hold” rating on the stock.
• 5/5/2026 – Inspire Medical Systems had its price target lowered by Wells Fargo & Company from $70.00 to $56.00. They now have an “equal weight” rating on the stock.
• 5/5/2026 – Inspire Medical Systems had its price target lowered by Mizuho from $70.00 to $55.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Inspire Medical Systems had its price target lowered by Robert W. Baird from $63.00 to $50.00. They now have a “neutral” rating on the stock.
• 5/5/2026 – Inspire Medical Systems had its “neutral” rating reaffirmed by Bank of America Corporation. They now have a $53.00 price target on the stock.
• 4/15/2026 – Inspire Medical Systems had its price target lowered by Truist Financial Corporation from $70.00 to $64.00. They now have a “hold” rating on the stock.
• 4/14/2026 – Inspire Medical Systems had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $56.00 price target on the stock.
• 4/14/2026 – Inspire Medical Systems was downgraded by Zacks Research from “strong-buy” to “hold”.
• 4/13/2026 – Inspire Medical Systems had its price target lowered by Mizuho from $85.00 to $70.00. They now have an “outperform” rating on the stock.
• 4/10/2026 – Inspire Medical Systems had its price target lowered by Stifel Nicolaus from $85.00 to $70.00. They now have a “buy” rating on the stock.
• 3/23/2026 – Inspire Medical Systems was upgraded by Zacks Research from “hold” to “strong-buy”.

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.